Literature DB >> 28710954

Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy.

W Boisseau1, M Touat2, G Berzero3, J Savatovsky4, A Marabelle5, V Touitou6, D Ricard7, G Malouf8, D Psimaras9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28710954     DOI： 10.1016/j.ejca.2017.05.036

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  8 in total

Review 1.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

Review 2.  Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.

Authors:  M Villagrán-García; R Velasco
Journal:  Neurol Sci       Date:  2022-02-17       Impact factor: 3.830

Review 3.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

4.  Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Authors:  Luca Diamanti; Alberto Picca; Paola Bini; Matteo Gastaldi; Enrico Alfonsi; Anna Pichiecchio; Eugenia Rota; Roberta Rudà; Francesco Bruno; Veronica Villani; Edvina Galiè; Alberto Vogrig; Mariarosaria Valente; Marco Zoccarato; Valentina Poretto; Bruno Giometto; Carolina Cimminiello; Michele Del Vecchio; Enrico Marchioni
Journal:  Neurol Sci       Date:  2021-08-23       Impact factor: 3.307

Review 5.  The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma.

Authors:  Lavinia Spain; Rachel Wong
Journal:  Melanoma Manag       Date:  2019-05-31

Review 6.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

7.  Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Authors:  A Boilève; M I Carlo; P Barthélémy; S Oudard; D Borchiellini; M H Voss; S George; C Chevreau; J Landman-Parker; M-D Tabone; D D Chism; A Amin; M A Bilen; D Bosse; A Coulomb-L'hermine; Xiaoping Su; T K Choueiri; Nizar M Tannir; Gabriel G Malouf
Journal:  J Immunother Cancer       Date:  2018-12-27       Impact factor: 13.751

Review 8.  Immune Checkpoint Inhibitors and Neurotoxicity.

Authors:  Zhiyi Zhao; Chunlin Zhang; Lian Zhou; Pan Dong; Lei Shi
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.